Ligases Enzyme Market Insights, Growth, Share, Size, Demand: 2024-2033

"The new report published by The Business Research Company, titled Ligases Enzyme Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the ligases enzyme market size has grown rapidly in recent years. It will grow from $2.89 billion in 2023 to $3.21 billion in 2024 at a compound annual growth rate (CAGR) of 11.3%. The ligases enzyme market size is expected to see rapid growth in the next few years. It will grow to $4.92 billion in 2028 at a compound annual growth rate (CAGR) of 11.2%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=12226&type=smp

Ligase Enzymes Market Surge Addressing The Rising Tide Of Cancer And Genetic Disorders
The increasing prevalence of cancer and genetic disorders is expected to propel the growth of the ligase's enzyme market going forward. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells, and genetic disorders refer to a wide range of medical conditions caused by abnormalities or mutations in an individual's genetic material, particularly in their DNA. Ligases enzymes are essential for DNA replication, repair, and recombination. In cancer, ligases can be used to repair damaged DNA, leading to the uncontrolled growth of cells. Ligases can also be used to target and kill cells with genetic disorders. For instance, in June 2023, according to the reports shared by the Centers for Disease Control and Prevention, a US-based government agency, in the United States, 1,603,844 new instances of cancer were reported in 2020, and 602,347 cancer-related deaths were recorded. Furthermore, 403 new cancer cases and 144 cancer-related deaths were reported for every 100,000 people. Furthermore, in February 2023, according to Gene People UK, a UK-based registered charity group, around 1 in 25 children are affected by a genetic condition in the UK, leading to more than 2.4 million children and adults in the UK living with a genetic disorder, and 30,000 babies and children are newly diagnosed each year. Therefore, the increasing prevalence of cancer and genetic disorders is driving the growth of the ligase's enzyme market.

Product Innovations In The Ligase Enzymes Market
Product innovation is a key trend gaining popularity in the ligase's enzyme market. Major companies operating in the ligase's enzyme market are developing innovative ligases enzymes to sustain their position in the market. For instance, in December 2021, ArcticZymes Technologies ASA, a Norway-based biotechnology company, launched ArcticZymes R2D Ligase, an innovative patent-pending ligase with novel specificity enabling the ligation of DNA to both ends of RNA using a DNA splint. The enzyme is projected to be widely applicable in molecular diagnostics, next-generation sequencing, and gene and RNA synthesis applications for possible therapeutic applications. Additionally, it has a unique substrate specificity that allows it to ligate DNA to both the 5'- and the 3'-ends of RNA in the presence of a DNA template, positioning the lightable ends of DNA and RNA. It is highly active and efficient, making it ideal for various applications.

The ligases enzyme market covered in this report is segmented -

1) By Type: E. coli DNA ligase, T4 DNA Ligase, Mammalian Ligases, Thermostable Ligases
2) By Source: Microorganisms, Animal, Plant
3) By Application: Ligase Chain Reaction (LCR), Ligase Detection Reaction (LDR), Next-Generation Sequencing (NGS), Repeat Expansion Detection (RED), Rolling Circle Amplification (RCA), Proximity Ligation Assay (PLA), Molecular Cloning, Ligation Mediated PCR, Mutation Detection
4) By End-User: Research Laboratories And Institutions, Pharmaceutical And Biopharmaceutical Companies, Diagnostic Laboratories

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=12226&type=discount

Major companies operating in the ligases enzyme market report are BASF SE, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Merck KGaA, Becton Dickinson And Company (BD), Agilent Technologies Inc., Illumina Inc., QIAGEN N.V., Novo Holdings AS, GenScript, VWR International, R And D Systems Inc., Promega Corporation, Oxford Nanopore Technologies Limited, Takara Bio Inc., New England Biolabs Inc., BioVision Inc., Enzo Life Sciences, Zymo Research, LGC Biosearch Technologies, Genetix Biotech Asia Pvt. Ltd., BLIRT S.A., Jena Bioscience, Bioline, Creative Enzymes, ArcticZymes Technologies ASA

Contents of the report:
1. Executive Summary
2. Ligases Enzyme Market Report Structure
3. Ligases Enzyme Market Trends And Strategies
4. Ligases Enzyme Market - Macro Economic Scenario
5. Ligases Enzyme Market Size And Growth
…..
27. Ligases Enzyme Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/ligases-enzyme-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

"Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide. "

This release was published on openPR.